Assessing observational studies of medical treatments

被引：24

作者：

Hartz A. ^{[1
]}

Bentler S. ^{[1
]}

Charlton M. ^{[1
]}

Lanska D. ^{[2
]}

Butani Y. ^{[1
]}

Soomro G.M. ^{[3
]}

Benson K. ^{[4
]}

机构：

[1] University of Iowa, College of Medicine, Department of Family Medicine, Iowa City

[2] VA Medical Center, Tomah, WI 54660

[3] Section of Community Psychiatry, St. George's Hospital Medical School, London

[4] Family Practice Clinic, North Colorado Medical Center, Greeley, CO

来源：

Emerging Themes in Epidemiology | / 2卷 / 1期

关键词：

comparative studies; epidemiologic research design; meta-analysis; reproducibility of results; reporting criteria for observational studies;

D O I：

10.1186/1742-7622-2-8

中图分类号：

学科分类号：

摘要：

Background: Previous studies have assessed the validity of the observational study design by comparing results of studies using this design to results from randomized controlled trials. The present study examined design features of observational studies that could have influenced these comparisons. Methods: To find at least 4 observational studies that evaluated the same treatment, we reviewed meta-analyses comparing observational studies and randomized controlled trials for the assessment of medical treatments. Details critical for interpretation of these studies were abstracted and analyzed qualitatively. Results: Individual articles reviewed included 61 observational studies that assessed 10 treatment comparisons evaluated in two studies comparing randomized controlled trials and observational studies. The majority of studies did not report the following information: details of primary and ancillary treatments, outcome definitions, length of follow-up, inclusion/exclusion criteria, patient characteristics relevant to prognosis or treatment response, or assessment of possible confounding. When information was reported, variations in treatment specifics, outcome definition or confounding were identified as possible causes of differences between observational studies and randomized controlled trials, and of heterogeneity in observational studies. Conclusion: Reporting of observational studies of medical treatments was often inadequate to compare study designs or allow other meaningful interpretation of results. All observational studies should report details of treatment, outcome assessment, patient characteristics, and confounding assessment. © 2005 Hartz et al; licensee BioMed Central Ltd.

引用

共 71 条

[1]

D'Agostino R., Kwan H., Measuring effectiveness. What to expect without a randomized control group, Med Care, 33, 4 SUPPL., (1995)

[2]

Pocock S., Randomized Trials or Observational Tribulations?, N Eng J Med, 342, 25, pp. 1907-1908, (2000)

[3]

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial, JAMA-J Am Med Assoc, 288, 3, pp. 321-333, (2002)

[4]

Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J., A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease, Ann Intern Med, 133, 12, pp. 933-941, (2000)

[5]

Heckbert S.R., Weiss N.S., Koepsell T.D., Lemaitre R.N., Smith N.L., Siscovick D.S., Lin D., Psaty B.M., Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women, Arch Intern Med, 157, 12, pp. 1330-1336, (1997)

[6]

Bush T.L., Barrett-Connor E., Cowan L.D., Criqui M.H., Wallace R.B., Suchindran C.M., Tyroler H.A., Rifkind B.M., Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study, Circulation, 75, 6, pp. 1102-1109, (1987)

[7]

Wilson P.W., Garrison R.J., Castelli W.P., Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study, N Engl J Med, 313, 17, pp. 1038-1043, (1985)

[8]

Sidney S., Petitti D.B., Quesenberry Jr. C.P., Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women, Ann Intern Med, 127, 7, pp. 501-508, (1997)

[9]

Humphrey L., Chan B.K., Sox H.C., Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease, Ann Intern Med, 137, 4, pp. 273-284, (2002)

[10]

Britton A., McKee M., Black N., McPherson K., Sanderson C., Bain C., Choosing between randomised and non-randomised studies: A systematic review, Health Technol Assess, 2, 13, (1998)

← 1 2 3 4 5 6 7 8 →